Cellavision Ab · OMXSTO:CEVI
Cellavision Ab — Shareholder Meeting (May 2014)
20 slides from Cellavision Ab's shareholder meeting presentation, May 12, 2014
Slide 1: CellaVision Annual General Meeting 2014
CellaVision Annual General Meeting 2014 1 5/12/2014
Slide 2: CellaVision's value creation
CellaVision’s value creation CellaVision creates value by improving processes for blood analysis, enabling more patients to recieve better and faster care at a lower cost to helathcare service. 2 5/12/2014
Slide 3: The automated testing process
The automated testing process Sample Analysis by Samples which taken. cell counter. show signs of disease are sent on for further analysis. 15 % 3 5/12/2014 3,8 billion
Slide 4: World leading supplier
World leading supplier of digital solutions for blood and body fluids analyses The hematology market • 3.8 billion blood cell analyses in cell counter a year. • About 15 percent of these samples require further analysis. • Potentiel world market: 15 000 laboratories. • Annual target market: 1 bilion
Slide 5: Market drivers
Market drivers Growing rationalization requirements in health care Global need for new technologies meeting increased demand for efficiency, quality and low cost solutions. 5 5/12/2014
Slide 6: Sales via the 4 major players
Sales via the 4 major players Parallel distribution channels increase market penetration. • Broad and efficient market penetration. Partners have global sales forces with local knowledge. • CellaVision’s products are often sold via large procurements in which laboratories increasingly require that p
Slide 7: Unique product offering
Unique product offering Analyzers, software and a minor part consumables 7 5/12/2014
Slide 8: Increased product portfolio 2013
Increased product portfolio 2013 1. DI-60, integrated in Sysmex’ automated hematology line, made a positive contribution to sales in Q3 and Q4. 2. CellaVision® Proficiency Software, a webb based product for internal and external quality assurance 1 2 and proficiency testing, was 3 successfully intro
Slide 9: CellaVision in short
CellaVision in short • Headquarters in Lund, Sweden. In total 70 employees. • Unique product offering to hospital and commercial laboratories. • Sales via the 4 major hema companies in the market. • Direct sales in the Nordic countries, the US, Canada and Japan. Business Support Office in China. • M
Slide 10: 2013: Growth 6%. Operating Margin 14,4%
2013: Growth: 6 %. Operating Margin: 14,4 % Sales, Personnel EBIT 200 30 180 25 160 140 20 120 Sales, MSEK 100 15 Personell, end of period 80 EBIT, MSEK Since the target was set 60 10 in 2010, sales growth has averaged 13.5 %. 40 5 20 0 0 07 08 09 10 11 12 13 10 5/12/2014
Slide 11: Strong close to 2013
Strong close to 2013 Q4 Q4 Full year Full year MSEK 2013 2012 2013 2012 Net sales +29 64,9 50,4 +6% 179,9 169,5 Gross profit 39,8 31,7 112,6 110,1 Operating profit 16,3 6,8 25,9 20,7 Operating margin % 25,1 13,5 14,4 12,2 Profit before tax 16,2 6,1 24,7 18,6 Cash flow 15,3 -6,4 11,6 -10,6 • Sales gr
Slide 12: Q4 2013: Sales per geographical market
Q4 2013: Sales per geographical market • Improved market 70 conditions in the US: + 50%. 60 50 10,2 7 12 1,5 2,5 • Continued strong sales in 40 1,9 1 14,8 7,6 9,5 6,8 16,6 China and Japan: +45%. 30 20 15 18,7 8,8 9,7 16,2 14,2 • Weak economic situation in 10 23,5 22,2 27,5 28,5 10,8 18,8 19,4 42,7 2
Slide 13: Achievements 2013
Achievements 2013 Two new products Parallel sales channels also in 1. DI-60, integrated in Sysmex’ Europe automated hematology line, • Agreements with the four main made a positive contribution players. to sales in Q3 and Q4. Global expansion 2. CellaVision® Proficiency • Increased efforts in China
Slide 14: Strategies for growth 2014
Strategies for growth 2014 1. Global expansion Growth region Asia Pacific in focus. 2. Partnerships Activities for enhanced cooperation in focus (training and market support). 3. Product development New products to existing target group, including an application for the analysis of red blood cells.
Slide 15: Strong cash flow and successful product development Q1 2014
Strong cash flow and successful product development Q1 2014 Jan–Mar Jan–Mar Jan–Dec (MSEK) 2014 2013 2013 Net Sales 43,2 33,8 179,9 Gross Profit 28,0 22,0 112,6 Operating Profit 7,5 -0,7 25,9 Operating Margin, % 17,4 Neg 14,4 Profit before tax 7,4 -1,5 24,7 Cash Flow 18,3 6,3 11,6 15 5/12/2014
Slide 16: Sales by geographical region, MSEK Q1 2014
Sales by geographical region, MSEK Q1 2014 70 60 10,2 50 7 12 1,5 2,5 40 1,9 9,5 1 6,8 14,8 7,6 30 8,8 16,6 15 18,7 9,7 16,2 20 14,2 10 23,5 22,2 27,5 28,5 10,8 18,8 19,4 42,7 25,1 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2012 2013 2014 North America EMEA Asia Pacific 16 5/12/2014
Slide 17: Significant events after the period close
Significant events after the period close • Introduction of two new products – CellaVision® DM9600 and CellaVision® Advanced RBC Application. 17 5/12/2014
Slide 18: Shareholders March 31 2014
Shareholders March 31 2014 Shareholders % Number of shareholders 2500 Stiftelsen Industrifonden 15,0 Christer Fåhraeus incl companies 10,1 2000 Metallica Förvaltnings AB 10,0 1500 Avanza Pension Försäkring AB 4,9 Livförsäkrings AB Skandia 4,1 1000 Nordnet Pensionsförsäkring AB 3,2 500 Tredje AP-fond
Slide 19: Board and Management
Board and Management Management Board Magnus Blixt 2/5 2013 Yvonne Mårtensson Magnus Blixt Göran Granqvist Lars Gatenbeck Christer Fåhraeus Sven-Åke Henningsson CEO CFO VP Quality Ordförande Stefan Bengtsson Karin Dahllöf Ron Hagner Lars Henriksson Roger Johanson Anna Malm Bernsten COO VP Sales & Ma
Slide 20: Learn more!
Learn more! • Web: www.cellavision.com • Blog: http://blog.cellavision.com • App: CellAtlas® – 90,000 users! 20 5/12/2014